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Objective: To assess the impact of the implementation of neonatal screening on hospital-
ization and death rates due to sickle cell disease in patients from the state of Maranhão,
Brazil.
Methods: A descriptive study was performed of all inpatients and deaths of patients with
a  diagnosis of sickle cell disease in Maranhão between 1999 and 2012. Data were collected
from the Hospital Information System of the Brazilian National Health Service (SUS) and
the  Death Information System of the Ministry of Health. The implementation of newborn
screening tests in Maranhão took place in 2005, and so the periods 1999–2005 (pre) and
2006–2012 (post) were analyzed for trend analysis using a multiple linear regression model.
Fisher’s exact test was used for the analysis of categorical variables and the Kruskal–Wallis
test  for continuous variables.
Results: The rate of hospitalization increased from 0.315 (pre) to 1.832 (post), indicating 5.82
times  more admissions (p-value = 0.04). The mortality rate increased from 0.115 to 0.216, that
is  1.88 times higher, but this was not statistically signiﬁcant (p-value = 0.586). The median
age  at admission dropped from 11.4 years to 8.7 years (p-value = 0.0002), whereas the median
age  at death increased from 10 years to 14 years (p-value = 0.665).
Conclusion: The increases in the rates of hospitalization and death after the implementation
of neonatal screening suggests that previously there was an underdiagnosis of sickle cell
disease and that screening, along with other factors, increased “visibility” in the state of
Maranhão.
©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Rua Barão de Itapary, 227, Centro, 65020-070
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emoglobin (Hb) S originated in Africa where the mutation
n the beta-globin gene was advantageous insomuch as het-
rozygotes have more  resistance against malaria.1 In Brazil,
ickle cell disease (SCD), the most prevalent hereditary dis-
ase, affects the black population most. It is estimated that
bout 45% of the Brazilian population and 72% of the pop-
lation of the state of Maranhão is of African descendancy.
oreover, in Brazil there are 25–30,000 SCD patients with 3500
ew cases diagnosed annually.2 In Maranhão there is an inci-
ence of 72 cases per 100,000 live births (1:1389) for SCD with
ne carrier of the sickle cell trait in every 30 births.2
In recent years, in countries like the USA, there has been
 signiﬁcant improvement in the survival of SCD patients. In
973, the estimated mean age at death of SCD patients in the
SA was 14.3 years, with 50% of deaths occurring during the
rst ﬁve years of life.3 In 1992, a study in the USA showed that
he mean age at death had increased to 42 years for men  and
o 48 years for women. In this study, the pattern of mortal-
ty varied with age and there was a peak incidence of death
mong SCD children occurring between one and three years of
ge; deaths of under 20-year-old patients were predominantly
ue to pneumococcal sepsis.4
Measures such as neonatal screening, the use of pro-
hylactic penicillin between three months and ﬁve years
f age, vaccination for pneumococcus, meningococcus and
aemophilus, and training in respect to early recognition of
plenic sequestration, reduced the mortality rate to less than
% in the ﬁrst ﬁve years of life.5 The authors concluded that
hese measures resulted in, on average, over 85% of affected
hildren surviving beyond the age of 20.5
In Brazil, research on hemoglobinopathies, in particular
ickle cell anemia, occurred after the government Ordinance
o. 822 came into force on June 6, 2001; this law was designed
o improve early diagnosis and to provide adequate treatment
ithin the ﬁrst few months of life. In December 2002, a test
o diagnose hemoglobinopathies was implanted in the state
f Maranhão.6 The test was performed by the Association of
arents and Friends of Exceptional Children (APAE) in the city
f São Luís, and by 2005 it was applied to 72% of all live births
n the state.6
The objective of the current study was to compare trends in
he mortality and hospital admission rates of SCD patients in
aranhão before and after the implementation of the neona-
al screening test.
ethods
ata related to the deaths and hospitalizations of SCD patients
n Maranhão from 1999 to 2012 were collected. Data related
o the hospitalizations were obtained from an abbreviated
ersion of the Hospital Information System (SIH) of the Brazil-
an National Health Service (SUS) annual database and data
elated to deaths were obtained from the Death Information
ystem (SIM/SUS). The cases were selected using the 10th revi-
ion of the International Classiﬁcation of Diseases (ICD-10)
odes for SCD: D57.0 (SCD with crisis), D57.1 (SCD without2 0 1 5;3 7(1):12–16 13
crisis), D57.2 (double heterozygous sickle cell disorders) and
D57.8 (other sickle cell disorders). Two age groups were deter-
mined: 0–19 years and 20 years or more.  The period 1999–2005
was considered the pre-screening test implementation period
and 2006–2012 was considered the post-implementation
period. Although the test ofﬁcially started in Maranhão in
December 2002, it actually achieved true coverage from 2005
onwards. The rates of hospitalization and mortality due to SCD
were calculated per 100,000 inhabitants. The total population
served as the denominator because in Maranhão Black peo-
ple make up 74% of the population and this methodology has
already been reported in the literature and will allow com-
parisons between the results of this study and others.7,8 The
annual population data were obtained from the Brazilian Insti-
tute of Geography and Statistics (2000, 2010 and population
estimates) and the total population of Maranhão grew from
5,418,354 to 6,714,314 between 1999 and 2012.
The rates of hospitalization and mortality due to SCD were
calculated according to the following formula:
Mortality rate
=
(
no of deaths due to sickle cell disease
population
× 100, 000
)
Hospitalization rate
=
(
no of hospitalizations
total resident population in year
× 100, 000
)
Fisher’s exact test was used to compare the percentage dis-
tribution of individuals by gender and age between the two
periods. The non-parametric Kruskal–Wallis test was used to
compare the median age between the periods.
To analyze the trend, a model of the evolution of the results
in the initial period was created using multiple regression to
check linear and quadratic models, with and without expo-
nential growth, and the model that best ﬁt the data was
used. After analyzing the trends, R2 values, and the results of
the adjustments of regression analysis, a simple linear trend
model was used to analyze the mortality and hospitalization
rates. Extrapolation was subsequently performed for the ﬁrst
period, which would be the ‘natural’ trend. The effect of the
‘natural’ trend was then removed (detrended) for both periods
and the means of the two  periods were compared using the
t-test for two groups. A value of signiﬁcance of 0.05, which
corresponds to a conﬁdence level of 95%, was assumed for
statistical analysis.
Results
Hospitalization  rates
Totals of 128 and 840 SCD patients were hospitalized in the
pre-test (before 2005) and post-test periods, respectively.
The median ages by year at admission ranged from eight
to 35 years old. When the results of the two periods were
compared, the median fell from 11.4 years in the pre-test
period to 8.7 years in the post-test period (p-value = 0.0002 –
Kruskal–Wallis).
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Linear trendPost testPre-testFigure 1 – Evolution of mortality and hospitalization rates.
The percentage of males was slightly higher than that of
females; 53.9% in the pre-test period and 51.9% in the post-test
period.
Figure 1 shows that in the pre-test period there were much
fewer hospitalizations, with a marked upward trend in the
post-test period. The mean hospitalization rate increased
5.82-fold from 0.315 in the pre-test period to 1.832 in the
post-test period. The t-test was used to check if the mean
hospitalization rate of the new period was different to the
old considering detrended data, i.e. considering the ‘natural’
trend where a change in the mean would indicate a change
in the trend; a descriptive level of 0.040 was obtained, from
which it was concluded that the trend in the hospitalization
rate changed signiﬁcantly.
Figure 2 shows the ﬁnal model for the hospitalization rate
in the period 1999–2005. The majority of points from 2006
onwards are above the line, indicating that there was a change,
an increase in the rate of hospitalization.
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Figure 2 – Final model for hospitalization.Figure 3 – Final model for mortality.
Mortality  rate
Forty-seven patients died in the pre-test period and 107 died in
the post-test period. The median ages at death by year ranged
from six to 26 years. When the results between the two  periods
were compared it was noted that the medians were higher in
the post-test period, with the median increasing from 10 years
old in the pre-test period to 16 years in the post-test period
(p-value = 0.247 – Kruskal–Wallis).
Figure 1 shows the trend in deaths over the years; there
was already an increasing trend in the pre-test period and this
trend continued in the post-test period, but with greater vari-
ability. The mean mortality rate increased by 1.88 times from
0.115 in the pre-test period to 0.216 in the post-test period.
Detrended data were used to check whether the mean in the
post-test period was different from that of the pre-test period
using the same procedure as the hospitalization rates. The
t-test of both groups gave a descriptive level of 0.586, from
which it was concluded that the trend in hospitalizations did
not change signiﬁcantly.
Figure 3 shows the ﬁnal model for the mortality rate. If the
death rate had continued at the same level, the values for
future years would have been close to the extrapolated line.
If there had been a signiﬁcant change in the mortality rate
due to the screening test, the majority of the points from 2006
onwards would be above the line. In this graph, it can be seen
that from 2006 onwards some points are above the line, others
are around the line, and some are below.
Discussion
In the present study, the mean hospitalization rate increased
signiﬁcantly from 0.315 in the period prior to the implemen-
tation of the neonatal screening test to 1,832 in the post-test
period. One of the hypotheses for this increase is the better
oter. 
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eporting of cases requiring hospital care. One of the causes
f under-reporting is the difﬁculty of making a diagnosis.
his problem was reduced with the implementation of the
eonatal screening program, which probably facilitated the
arly diagnosis of SCD children, thereby raising the number
f hospital admissions. Other causes of under-reporting could
nclude poor hospital care, the incorrect use of ICD codes, and
he lack of hospital registration with no consequent recording
n the SIH/SUS system of cases which remained emergencies
hroughout the period of hospital treatment.
Despite progress, the hospitalization rate in Maranhão is
till far below the national average. A Brazilian study,7 based
n data from the SIH/SUS for 2002, reported hospitalization
ates for SCD of 1.8 in the state of Bahia, and 6.0 and 7.0
or the states of São Paulo and Rio de Janeiro, respectively.
hese states have the following percentages of black popula-
ion: Bahia: 78.8%; Maranhão: 74.3%; São Paulo: 45.3% and Rio
e Janeiro: 30.9%.9
Given that the overall prevalence of SCD in the black popu-
ation is 0.22%,9 the expected number of cases in 2002 would
ave been 11,339 in Bahia, 9486 in Maranhão, 10,191 in Rio de
aneiro, and 10,918 in São Paulo. In other words, the expected
umber of cases in the four states would be very similar, and
hus the hospitalization rates should have been very similar.
owever, the actual hospitalization rates are much higher in
io de Janeiro and São Paulo. Currently, the rate of hospital-
zation in Maranhão is 1,832, similar to the state of Bahia, but
bout 3–4 times less than the states of São Paulo and Rio de
aneiro in that study.7
It is possible that the low hospitalization rates in Maranhão
ccur not only due to under-reporting of patients who required
ospital treatment, but also due to the low level of hospital
are for patients with SCD in the state. Under-reporting of
atients was reduced after the implementation of the neona-
al screening test. This analysis infers that the hospitalization
ates for SCD are a reﬂection of the quality of medical care pro-
ided to patients and the social differences that exist between
razilian regions.
After the implementation of the neonatal screening test
n Maranhão there was a signiﬁcant reduction in the median
ge of hospitalized SCD patients, from 11.4 years in the
re-test period to 8.7 years in the post-test period. This
hows the initial impact of the test on the youngest age
roups. The data reﬂect the national reality as the 2002 Brazil-
an study7 reported that hospitalizations were generally of
ounger patients, with most being under the age of 29 years,
nd around 70% under 19 years. The median ages were 11
ears in Bahia, and 12 years in Rio de Janeiro and São Paulo.
Conﬁrming a reduction in the under-registration of deaths
ttributed to SCD caused by a lack of diagnosis, the present
tudy noted that there was an increase, albeit insigniﬁcant,
n the mean mortality rate of almost 200% from the pre-test
eriod to the post-test period. It is believed that there was
o statistical signiﬁcance for this increase due to the great
ariability in the post-test period (in 2009, in particular, and in
012 there were decreases) and that the number of deaths in
ach group was small.
The median age at death was very low (ten years in the pre-
est period and 14 in the post-test period) with no signiﬁcant
ifference between the two periods. At the national level, the2 0 1 5;3 7(1):12–16 15
median age at death is about twice that in Maranhão. In 2002,
the median age at death for SCD patients was 26.5 years in
Bahia; 31.5 in Rio de Janeiro and 30.0 in São Paulo.7 The current
situation in Maranhão is comparable to that of Brazil in 1996,
when the median reported age at death was 18.5 years.10
SCD patients live much longer in some other countries. The
aforementioned US cohort study reported that the median age
at death was 42 years for men  and 48 for women. For patients
with Hb SS it was 60, and for patients with the Hb SC geno-
type it was 68.4 Another cohort study performed in Jamaica
reported a median age at death of 53 years for men  and 58.5
years for women with Hb SS.11 The mean age at death in SCD
patients seems not to have changed since studies conducted
by Platt et al. in the early 1990s because a recent study exam-
ining the age at death using death certiﬁcate data from the US
National Center for Health Statistics showed that in the US in
2005, considering all the genotypes, the median age at death
of SCD patients was 42 years for women and 38 years for men.8
Perhaps this particular study had an inherent bias because if
patients with SCD live longer it is less likely that their death
certiﬁcate will include sickle cell disease as the cause.
In the current study, it was not expected that there would be
a change in the age at death, but only in the absolute number of
recorded deaths due to improved notiﬁcation. In a future anal-
ysis, in some decades, when patients diagnosed by screening
reach adulthood, it may be possible to observe an increase in
the median age at death in Maranhão.
The present study has shown that the implementation of
a neonatal screening test for hemoglobinopathies has not yet
resulted in an increase in the survival of patients with SCD
in Maranhão, when one considers the low age at death and
the marked difference between the ages at death compared to
elsewhere in Brazil, and internationally.
Prompt diagnosis of the disease on its own is not enough
to have a positive impact on patient survival. This has been
observed in two Brazilian cohort studies related to neonatal
screening (one in the state of Minas Gerais and the other in
the state of Rio de Janeiro) where it was observed that even
with a carefully controlled program, the probability of chil-
dren with Hb SS dying was still considered to be high, with
71.8% of deaths occurring in under two-year-old children.12
Infections and splenic sequestration13 were the main causes
of death, and 23% of deaths occurred outside the hospi-
tal environment.12 It is clear that in addition to a neonatal
screening test for hemoglobinopathies it is necessary to opti-
mize other measures, such as family counseling about the
serious complications of the disease, effective vaccination and
drug distribution programs, as well as access to effective med-
ical care to treat clinical complications. On the other hand,
the socioeconomic characteristics of the population also inﬂu-
ence the survival of SCD patients and, according to some
researchers,14 the presentation and severity of the disease
depend on socioeconomic status, nutrition, preventive meas-
ures and access to health services. These are all relevant issues
in Maranhão, which has one of the worst human development
indexes (HDI = 0.639) in Brazil; the state was in the second from
15bottom position overall of Brazilian states in 2010.
Despite the fact that the SIH/SUS encompasses the major-
ity of hospital admissions in Brazil, a limitation of the present
study is the validity of information provided by the SIH/SUS.
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It is possible that not all the health facilities in the state
of Maranhão that care for SCD patients systematically regis-
ter their admissions in the SIH/SUS system. This leads to an
under-estimation of the frequency of hospitalizations. Failure
to properly complete ICD information may well be another
limitation in accurately checking the occurrence of hospital-
izations for SCD.
The under-reporting of deaths is a problem in the state
of Maranhão. However, the situation has improved in recent
years, when the notiﬁcation of deaths increased from 48.8%
in 2001 to 70% in 2011. Nevertheless, this is much lower than
in states in the south and southeast of Brazil, where the ﬁgure
has been close to 100% since 1991.16 Another limiting factor is
the quality of information.
It is concluded that the key reason for the apparent para-
dox of increased mortality and hospitalization rates after the
implementation of neonatal screening is the increased ‘visi-
bility’ of SCD, which is primarily due to physicians, who are
responsible for ﬁlling out death certiﬁcates and diagnostic
data required to authorize hospital admittance.
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